Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 30,941 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03. Following the completion of the sale, the chief operating officer owned 434,188 shares of the company’s stock, valued at $6,439,008.04. This trade represents a 6.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total transaction of $258,453.60.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total transaction of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total transaction of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total transaction of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total transaction of $251,210.80.
• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total transaction of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total transaction of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total transaction of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total transaction of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total transaction of $285,672.80.

Adaptive Biotechnologies Stock Up 8.2%

Shares of NASDAQ ADPT traded up $1.13 during midday trading on Wednesday, hitting $14.84. The company had a trading volume of 2,188,850 shares, compared to its average volume of 2,046,190. Adaptive Biotechnologies Corporation has a twelve month low of $6.77 and a twelve month high of $20.76. The business has a 50-day simple moving average of $15.17 and a two-hundred day simple moving average of $15.98. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -37.10 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the firm posted ($0.23) EPS. The firm’s revenue for the quarter was up 51.0% on a year-over-year basis. On average, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of ADPT. Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies in the fourth quarter valued at approximately $65,942,000. Price T Rowe Associates Inc. MD grew its holdings in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the period. Ameriprise Financial Inc. grew its holdings in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the period. Invesco Ltd. grew its holdings in Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after purchasing an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ADPT has been the topic of a number of analyst reports. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a report on Friday, February 6th. BTIG Research increased their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Guggenheim increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.